Key points on systemic sclerosis-associated interstitial lung disease from the 2025 ERS/EULAR clinical practice guideline for tissue diseases-associated ILD
10.3760/cma.j.cn141217-20250618-00194
- VernacularTitle:2025版《EULAR/ERS：结缔组织病相关间质性肺疾病管理指南》中SSc-ILD要点解读
- Author:
Xuezhi HONG
1
;
Yanhua XIAO
;
Minrui LIANG
;
Hanyou MO
Author Information
1. 赣南医科大学第一附属医院风湿免疫科，赣州 341000
- Publication Type:Journal Article
- Keywords:
Systemic sclerosis;
Interstitial lung disease;
Clinical practice guidelines;
Therapy;
Screening;
Follow-up
- From:
Chinese Journal of Rheumatology
2025;29(10):809-812
- CountryChina
- Language:Chinese
-
Abstract:
In 2025, the European League Against Rheumatism(EULAR) and the European Respiratory Society(ERS) jointly released the first clinical practice guidelines for the management of connective tissue disease-associated interstitial lung disease (CTD-ILD), with a particular focus on systemic sclerosis-associated ILD(SSc-ILD). Based on evidence-based principles, the guidelines provide a comprehensive framework encompassing screening, progression assessment, therapeutic strategies, and follow-up. Notably, the guidelines emphasize the clinical value of combination therapy for patients at high risk or with rapidly progressive disease. This article summarizes and interprets the key recommendations, including HRCT-based screening, multi-dimensional assessment tools, stratified pharmacological strategies, classification of drug mechanisms, and risk-duration-based follow-up protocols. It aims to provide up-to-date international guidance for clinical decision-making and research in the management of SSc-ILD.
